HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
 Help
Order: Signal: Tickers:
Filters
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
Total: 200 #191 Type: candle | line | technical    Timeframe: daily | intraday    Auto Refresh: 3min | off
TickerMAIA [AMEX]
CompanyMAIA Biotechnology, Inc.
CountryUSA
IndustryBiotechnology
Market Cap43.11MEPS (ttm)-1.48
P/E-EPS this Y-88.40%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-25.00%
Dividend-Sales Q/Q-
Insider Own25.40%Inst Own-
Insider Trans0.01%Inst Trans-
Short Float0.33%Earnings-
Analyst Recom-Target Price-
Avg Volume1.21M52W Range3.52 - 9.64
Sep-08-22 08:00AMMAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference Business Wire
Sep-06-22 08:00AMMAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022 Business Wire
Aug-30-22 11:07AMMAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids Business Wire
Aug-22-22 08:00AMMAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update Business Wire
Aug-02-22 08:00AMMAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC) Business Wire
Aug-01-22 03:30PMMAIA Biotechnology Announces Closing of Initial Public Offering Business Wire
Jul-27-22 07:52PMMAIA Biotechnology Announces Pricing of Initial Public Offering Business Wire
TickerSWTX [NASD]
CompanySpringWorks Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap1.39BEPS (ttm)-4.67
P/E-EPS this Y-240.70%
Forward P/E-EPS next Y0.60%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B4.20EPS Q/Q-44.90%
Dividend-Sales Q/Q-
Insider Own1.40%Inst Own-
Insider Trans-28.19%Inst Trans13.14%
Short Float22.97%Earnings-
Analyst Recom2.00Target Price77.80
Avg Volume988.11K52W Range13.60 - 77.70
Sep-07-22 09:56AMSpringWorks Therapeutics Announces $225 Million Private Placement Financing GlobeNewswire
Sep-07-22 09:55AMSpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma GlobeNewswire
Aug-19-22 06:30AMSpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022 GlobeNewswire
Aug-04-22 06:30AMSpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights GlobeNewswire
Aug-02-22 07:00AMSpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-15-22 06:30AMSpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors GlobeNewswire
Jul-06-22 11:38AMHC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging Benzinga
Jun-13-22 09:04AMSpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch Benzinga
Jun-10-22 06:30AMSpringWorks Therapeutics to Present Progress Across the Companys Targeted Oncology Portfolio at Virtual R&D Day GlobeNewswire
Jun-09-22 07:00AMSpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference GlobeNewswire
TickerALNY [NASD]
CompanyAlnylam Pharmaceuticals, Inc.
CountryUSA
IndustryBiotechnology
Market Cap25.78BEPS (ttm)-8.16
P/E-EPS this Y3.50%
Forward P/E-EPS next Y49.90%
PEG-EPS past 5Y-8.50%
P/S29.15EPS next 5Y7.86%
P/B143.05EPS Q/Q-42.60%
Dividend-Sales Q/Q1.90%
Insider Own0.10%Inst Own99.10%
Insider Trans-30.45%Inst Trans0.21%
Short Float4.19%EarningsJul 28/b
Analyst Recom2.20Target Price231.27
Avg Volume1.00M52W Range117.58 - 236.80
Sep-08-22 02:30AMAlnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Business Wire
Sep-07-22 06:30AMArch, a16z back Alnylam co-founder's next big RNA play American City Business Journals
Sep-06-22 08:00AMAlnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference Business Wire
Sep-04-22 10:45AMWant to Beat Alphabet Stock? Buy These 2 Winners of the Bear Market Motley Fool
Aug-31-22 11:30AMEmergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound? Zacks
Aug-29-22 11:40AMAlnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug Benzinga
Aug-29-22 08:00AMAlnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy Business Wire
Aug-26-22 01:35PMAlnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why Zacks
Aug-26-22 01:20PMPfizer 'surprised' by Moderna COVID-19 vaccine patent lawsuit Yahoo Finance
Aug-24-22 04:00PMAlnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors Business Wire
TickerNVTS [NASD]
CompanyNavitas Semiconductor Corporation
CountryIreland
IndustrySemiconductors
Market Cap810.87MEPS (ttm)-0.21
P/E-EPS this Y-701.60%
Forward P/E-EPS next Y29.00%
PEG-EPS past 5Y-
P/S28.65EPS next 5Y-
P/B2.76EPS Q/Q261.70%
Dividend-Sales Q/Q56.40%
Insider Own15.90%Inst Own26.20%
Insider Trans0.00%Inst Trans-3.01%
Short Float6.25%EarningsAug 15/a
Analyst Recom1.90Target Price10.00
Avg Volume1.32M52W Range3.51 - 22.19
Sep-07-22 06:00AMNavitas GaNSense Half-Bridge Power ICs: The Next Stage in the High Frequency Power Electronics Revolution GlobeNewswire
Aug-31-22 08:30AMNavitas, the Pure-play, Next-Gen Power Semiconductor Leader Announces New York Investor Meeting GlobeNewswire
Aug-29-22 05:54PMNavitas Pure-Play, Next-Gen Semi Growth Highlighted at Deutsche Bank 2022 Technology Conference GlobeNewswire
Aug-23-22 08:30AMNavitas Highlights Pure-Play, Next-Gen Power at Jefferies Semiconductor Investor Summit GlobeNewswire
Aug-22-22 06:00PMNavitas Present Pure-Play, Next-Gen Power Semiconductors (GaN & SiC) in China Renaissance Fire-side Chat and Non-Deal Roadshow GlobeNewswire
Aug-17-22 08:15AMNavitas Highlight Pure-Play, Next-Gen Power Semiconductors (GaN & SiC) at Baird Newly Public Company Virtual Access Day GlobeNewswire
Aug-15-22 04:08PMNavitas Semiconductor Announces Second Quarter 2022 Financial Results and Acquisition of GeneSiC, an Industry-leading SiC Company GlobeNewswire
Aug-15-22 04:04PMNavitas Semiconductor, Industry-Leader in Gallium Nitride Power ICs, Announces Acquisition of GeneSiC Semiconductor, Silicon Carbide Pioneer GlobeNewswire
Aug-15-22 08:30AMNavitas to Present Next-Gen Semiconductors at Taiwan Investor Fireside Chat GlobeNewswire
Aug-15-22 08:15AMNavitas 160W Ultra-fast Charger Powers OnePlus Flagship 10T Smartphone GlobeNewswire
TickerHOOK [NASD]
CompanyHOOKIPA Pharma Inc.
CountryUSA
IndustryBiotechnology
Market Cap77.14MEPS (ttm)-2.02
P/E-EPS this Y-36.10%
Forward P/E-EPS next Y14.70%
PEG-EPS past 5Y-
P/S6.43EPS next 5Y5.00%
P/B0.58EPS Q/Q42.80%
Dividend-Sales Q/Q-50.00%
Insider Own8.39%Inst Own65.50%
Insider Trans0.00%Inst Trans-3.39%
Short Float2.66%EarningsAug 11/b
Analyst Recom1.70Target Price5.88
Avg Volume328.80K52W Range1.25 - 6.89
Sep-07-22 07:00AMHOOKIPA Pharma to Participate in Upcoming Investor Conferences in September GlobeNewswire
Aug-11-22 08:15AMHOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Misses Revenue Estimates Zacks
Aug-11-22 07:00AMHOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates GlobeNewswire
Aug-04-22 07:00AMHOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022 GlobeNewswire
Jul-25-22 08:00AMFDA accepts HOOKIPAs Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer GlobeNewswire
Jul-08-22 07:27AMWhat Is The Ownership Structure Like For HOOKIPA Pharma Inc. (NASDAQ:HOOK)? Simply Wall St.
Jun-21-22 09:00AMHOOKIPA Announces Executive Leadership Changes GlobeNewswire
Jun-09-22 07:00AMHOOKIPA to Participate in the JMP Securities Life Sciences Conference GlobeNewswire
Jun-05-22 09:00AMHOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO GlobeNewswire
Jun-03-22 07:00AMPreclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium GlobeNewswire
TickerZY [NASD]
CompanyZymergen Inc.
CountryUSA
IndustrySpecialty Chemicals
Market Cap266.89MEPS (ttm)-3.54
P/E-EPS this Y-82.10%
Forward P/E-EPS next Y11.10%
PEG-EPS past 5Y-
P/S18.41EPS next 5Y20.30%
P/B1.03EPS Q/Q-14.10%
Dividend-Sales Q/Q-55.90%
Insider Own4.20%Inst Own60.60%
Insider Trans-1.82%Inst Trans-11.10%
Short Float3.62%Earnings-
Analyst Recom3.00Target Price2.30
Avg Volume1.58M52W Range1.10 - 14.43
Sep-06-22 11:21AMZymergen's problems were evident to board shortly after IPO, SEC filings show American City Business Journals
Aug-26-22 03:35PMLast of Zymergen's 3 founders to leave as synbio company preps for merger with 80 more layoffs American City Business Journals
Aug-15-22 12:28PMGinkgo Bioworks Lifts Guidance After Mixed Q2 Results; Shares Surge Investing.com
Aug-05-22 05:50AMWhy Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future Motley Fool
Aug-02-22 02:33PMIs Ginkgo Bioworks Putting Its $1.5 Billion Cash Hoard to Good Use? TheStreet.com
Jul-25-22 05:40PMGinkgo reaches deal to pay $83 million for Bayer's West Sac lab American City Business Journals
Jul-25-22 05:16PMIn wake of big deal, Zymergen cuts another 80 jobs, earmarks exec bonuses American City Business Journals
Jul-25-22 03:28PMThe Funded: On its way to a SPAC merger vote, Wag announced plans to donate shares American City Business Journals
Jul-25-22 02:47PMGinkgo Bioworks acquires competitor for $300M American City Business Journals
Jul-25-22 02:20PMGinkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal Benzinga
TickerNVTA [NYSE]
CompanyInvitae Corporation
CountryUSA
IndustryDiagnostics & Research
Market Cap797.42MEPS (ttm)-13.48
P/E-EPS this Y59.80%
Forward P/E-EPS next Y30.50%
PEG-EPS past 5Y9.90%
P/S1.59EPS next 5Y8.00%
P/B1.90EPS Q/Q-
Dividend-Sales Q/Q17.50%
Insider Own1.40%Inst Own84.10%
Insider Trans-5.38%Inst Trans5.55%
Short Float19.38%EarningsAug 09/a
Analyst Recom3.10Target Price2.71
Avg Volume18.83M52W Range1.83 - 32.93
Sep-07-22 10:26AM2 Cathie Wood Stocks That Soared 60% in August Motley Fool
Sep-06-22 11:18AMMeme-Stock Mania Is Leaving These Genomics Stocks TheStreet.com
Sep-01-22 10:00AMCathie Wood Has Been Buying These Two Stocks Relentlessly Motley Fool
Aug-30-22 04:05PMInvitae to Present at Upcoming Investor Conference PR Newswire
Aug-30-22 02:48PMExact Sciences: Don't Deem It Guilty by Association TheStreet.com
Aug-29-22 06:15AMInvitae Stock Wont Be Tripling Again Any Time Soon InvestorPlace
Aug-27-22 08:00AMIs It Too Late to Buy Invitae Stock? Motley Fool
Aug-25-22 12:10PMFulgent Genetics Seeks Post-Pandemic Growth TheStreet.com
Aug-23-22 05:52AMCould Another Short Squeeze Be on the Way for Invitae? Motley Fool
Aug-21-22 10:37AMIs There Any Hope for Invitae Stock? Motley Fool
TickerPEI [NYSE]
CompanyPennsylvania Real Estate Investment Trust
CountryUSA
IndustryREIT - Retail
Market Cap22.79MEPS (ttm)-25.69
P/E-EPS this Y45.20%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-38.60%
P/S0.08EPS next 5Y1.00%
P/B-EPS Q/Q45.00%
Dividend-Sales Q/Q-1.30%
Insider Own2.80%Inst Own9.60%
Insider Trans0.00%Inst Trans-0.89%
Short Float31.03%EarningsAug 09/b
Analyst Recom3.00Target Price-
Avg Volume119.83K52W Range3.24 - 30.75
Aug-30-22 06:55AMPREITs Community Commitment was Vivid this August PR Newswire
Aug-18-22 06:55AMCherry Hill Mall Continues to Attract New-to-Market Trailblazing Tenants PR Newswire
Aug-09-22 06:55AMPREIT Reports Second Quarter 2022 Results PR Newswire
Aug-02-22 04:30PMPREIT Board of Trustees Welcomes Two New Independent Trustees as Representatives for Preferred Shareholders PR Newswire
Aug-02-22 06:55AMPREIT Opens Q&A Platform for Shareholders Ahead of Second Quarter 2022 Earnings Call PR Newswire
Jul-21-22 06:55AMPREIT Schedules Second Quarter 2022 Earnings Release and Conference Call PR Newswire
Jul-19-22 06:55AMPREIT Delivers Expanding Retailers to New Markets PR Newswire
Jul-14-22 04:30PMPREIT Urges Preferred Shareholders to Cast their Votes for Preferred Share Trustee Nominees Prior to August 2, 2022 PR Newswire
Jul-08-22 01:23PMPREIT Urges Preferred Shareholders to Cast their Votes for Preferred Share Trustee Nominees Prior to August 2, 2022, and Addresses the Cygnus Capital Statement Issued July 7, 2022 PR Newswire
Jul-07-22 01:36PMCygnus Capital Issues Statement Regarding the Right of Holders of Preferred Shares of Pennsylvania Real Estate Investment Trust to Elect Two Board Trustees at the Recently Adjourned 2022 Annual Meeting of Shareholders PR Newswire
TickerGDRX [NASD]
CompanyGoodRx Holdings, Inc.
CountryUSA
IndustryHealth Information Services
Market Cap2.43BEPS (ttm)-0.12
P/E-EPS this Y94.20%
Forward P/E18.50EPS next Y28.96%
PEG-EPS past 5Y-36.00%
P/S3.02EPS next 5Y16.09%
P/B3.12EPS Q/Q-104.70%
Dividend-Sales Q/Q8.60%
Insider Own4.80%Inst Own85.80%
Insider Trans0.00%Inst Trans2.85%
Short Float19.34%EarningsAug 08/a
Analyst Recom2.70Target Price9.87
Avg Volume3.29M52W Range5.59 - 48.05
Aug-31-22 07:22PMTop after-hours movers: Okta, Disney, Five Below and more Yahoo Finance
Aug-31-22 05:20PMStocks moving in after hours: Okta, Veeva Systems, Five Below, GoodRx Yahoo Finance Video
Aug-31-22 10:45AMGot $5,000? These 2 Growth Stocks Are Near Their 52-Week Lows Motley Fool
Aug-29-22 04:05PMGoodRx to Present at the Goldman Sachs Communacopia + Technology Conference Business Wire
Aug-18-22 06:41AMWhy This Beaten-Down Stock Could Surprise Investors This Year Motley Fool
Aug-15-22 04:27PMThe Inflation Reduction Act will not 'fix American health care': GoodRx CEO Yahoo Finance
Aug-11-22 11:40AMELV vs. GDRX: Which Stock Is the Better Value Option? Zacks
Aug-09-22 05:21PMGoodRx Had Good News. Why the Stocks Rally Faded. Barrons.com
Aug-09-22 10:09AMNovavax, GoodRx stocks on the move after earnings Yahoo Finance Video
Aug-08-22 09:30PMGoodRx Holdings, Inc. (GDRX) Q2 2022 Earnings Call Transcript Motley Fool
TickerNMTC [NASD]
CompanyNeuroOne Medical Technologies Corporation
CountryUSA
IndustryMedical Devices
Market Cap31.11MEPS (ttm)-0.76
P/E-EPS this Y63.10%
Forward P/E-EPS next Y7.20%
PEG-EPS past 5Y-
P/S155.56EPS next 5Y-
P/B2.64EPS Q/Q31.00%
Dividend-Sales Q/Q-4.60%
Insider Own1.50%Inst Own21.40%
Insider Trans24.05%Inst Trans-6.77%
Short Float0.41%EarningsAug 11/a
Analyst Recom2.50Target Price2.62
Avg Volume182.90K52W Range0.51 - 5.06
Aug-11-22 04:00PMNeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update PR Newswire
Aug-09-22 09:00AMNeuroOne® Submits Special 510(k) to FDA for Evo® sEEG Electrode PR Newswire
Aug-04-22 09:00AMNeuroOne® to Report Third Quarter Fiscal Year 2022 Financial Results on August 11 PR Newswire
Aug-03-22 09:00AMNeuroOne® Announces $3.5 Million Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode PR Newswire
Jul-12-22 09:00AMNeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode PR Newswire
Jun-02-22 08:47AMNeuroOne® Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders PR Newswire
May-19-22 09:30AMNeuroOne® to Present Its Breakthrough Technology for Monitoring Neural Activity at the H.C. Wainwright Global Investment Conference on May 25 PR Newswire
May-16-22 04:30PMNeuroOne Provides Evo® sEEG Update PR Newswire
May-12-22 04:05PMNeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update PR Newswire
May-03-22 09:00AMNeuroOne® to Report Second Quarter Fiscal Year 2022 Financial Results on May 12 PR Newswire
prev1 ... 10 ... 151617181920
affiliate • advertise • contact • privacy • help
Do Not Sell My Data • Privacy Settings
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2022 FINVIZ.com. All Rights Reserved.